Saturday, November 21, 2026

Xenetic Biosciences Stock Impressive Drop 11% So Far On Thursday, Underperforms Market

Automated market report from our archive (2020-2024), published before source-traceability. How we work

Xenetic Biosciences Stock  Impressive Drop 11%  So Far On Thursday, Underperforms Market

(VIANEWS) - Shares of Xenetic Biosciences (NASDAQ: XBIO) slid by a staggering 11.02% to $0.40 at 13:14 EST on Thursday, following the last session's downward trend. NASDAQ is rising 0.49% to $12,055.31, after three successive sessions in a row of losses. This seems, up to now, a somewhat positive trend trading session today.

Xenetic Biosciences's last close was $0.43, 65.53% below its 52-week high of $1.25.

About Xenetic Biosciences

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. It is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.

Earnings Per Share

As for profitability, Xenetic Biosciences has a trailing twelve months EPS of $-1.704.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -39.85%.

More news about Xenetic Biosciences (XBIO).

Are you or your business in this article?

If something is wrong, out of context or missing, tell us. We correct errors with a dated note, and people named in an article can publish their response under it.

Correct, add context or respond →

Not a source? Spotted an error? Report an error

How this story was made

Spotted an error? Use “Correct this article” (bottom right), or select any sentence, to report it or respond to that point.

  1. Published before we listed source documents with each article.
  2. Published 6 Apr 2023
  3. No responses yet from the people or organisations in this story. Are you in this story? Respond on the record ›
  4. Part of the Via News record, fingerprinted daily so it cannot be quietly rewritten. What that means › · Report an error ›
ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.